Related Experiment Video
Updated: Mar 7, 2026
An Orthotopic Resectional Mouse Model of Pancreatic Cancer
Published on: September 24, 2020
Abstract:
The chromosome 18q21 deletion in nearly one third of pancreatic adenocarcinomas eliminates not only the tumor suppressor SMAD4, but also neighboring genes with important cellular roles, such as ME2 This is tolerated by cancer cells only because ME2 has a functionally redundant paralog, ME3, elsewhere in the genome. A study shows that these cells are vulnerable to ME3 silencing; this concept of collateral lethality could provide a new therapeutic strategy for a difficult-to-treat disease.
Insights
Pancreatic cancer cells with a common 18q21 deletion are vulnerable to ME3 gene silencing. This collateral lethality offers a potential new therapeutic strategy for this challenging disease.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Chromosome 18q21 deletions are prevalent in pancreatic adenocarcinomas, affecting tumor suppressor SMAD4 and neighboring genes like ME2.
- Cancer cells tolerate ME2 loss due to functional redundancy with its paralog, ME3.
Purpose of the Study:
- To investigate the therapeutic potential of targeting ME3 in pancreatic cancer cells with 18q21 deletions.
- To explore the concept of collateral lethality as a treatment strategy.
Main Methods:
- Gene silencing experiments targeting ME3 in pancreatic cancer cell lines.
- Analysis of cell viability and proliferation following ME3 inhibition.
Main Results:
- Pancreatic cancer cells with 18q21 deletions demonstrated significant vulnerability to ME3 gene silencing.
- Targeting ME3 induced cell death, highlighting a collateral lethality effect.
Conclusions:
- ME3 is a potential therapeutic target in pancreatic adenocarcinomas harboring 18q21 deletions.
- Collateral lethality, by targeting ME3, presents a novel strategy for treating pancreatic cancer.
